TAVR

Transcatheter aortic valve replacement (TAVR) is a key structural heart procedure that has rapidly expanded in the decade since it was first FDA cleared. TAVR has come a paradigm shift in how many aortic stenosis patients are treated, now making up more than 50% of U.S. aortic valve replacements. It is less invasive than open heart surgery and recovery times are greatly reduced. TAVR can also be used in patients who otherwise are too high risk to undergo surgery. TAVR is referred to as transcatheter aortic valve implantation (TAVI) in many placed outside of the U.S. TAVR inspired the growing areas of transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

When heart patients can’t wait: Urgent TAVR with self-expanding vs. balloon-expandable valves
The high-risk patients who require urgent or emergent TAVR are often excluded from major clinical trials. To learn more about this population, researchers explored data from nearly 600 patients treated at high-volume facilities.
Cleveland Clinic launches partnership focused on AI-powered TAVR planning
Cleveland Clinic, one of the world’s top heart hospitals, has launched a new two-part partnership with Ohio-based DASI Simulations.
Acute kidney injury after TAVR: Key risk factors every cardiologist should know
Multiple studies have linked acute kidney injury after TAVR to a heightened risk of short- and long-term mortality.
FDA approves JenaValve TAVR system for aortic regurgitation
The Trilogy Transcatheter Heart Valve System is the first TAVR device approved by the FDA to treat severe aortic regurgitation. Until now, interventional cardiologists have had to settle for the off-label use of TAVR valves built for treating aortic stenosis.
Moderate valve oversizing during TAVR boosts survival—too much may be less beneficial
Oversizing transcatheter heart valves can improve TAVR outcomes. There is still a reason to be cautious, however, especially when patients are receiving a balloon-expandable valve.

Medicare data reveal ‘highly concerning’ TAVR trends—are hospital rankings to blame?

Hospitals could be turning away high-risk heart patients to help their TAVR programs receive a higher ranking, according to new research published in JACC: Cardiovascular Interventions.

FDA clears TAVR guidewire built with BASILICA in mind

The Telltale system was designed to assist cardiologists when BASILICA is required prior to TAVR.

‘Strongest growth in over a decade’: Heart tech helps Medtronic beat earnings expectations

The company's PFA and TAVR technologies both played key roles in the successful second quarter. In addition, Medtronic expects its place in the renal denervation market to make a major impact going forward.

Boston Scientific ACURATE neo2 aortic valve system self-expanding TAVR valve

Did Boston Scientific pull the plug too early on TAVR devices? Cardiologists weigh in

Boston Scientific stopped selling its Acurate TAVR systems after they underperformed in a few key trials and failed to gain FDA approval. Was it the right call?

Early TAVR for asymptomatic severe AS cuts costs, improves outcomes

The study found lifetime per-patient savings from early TAVR ranged from about $2,334 in the U.K. to $19,607 in Switzerland.

Meril Life Sciences, an India-based medical device company founded in 2006, developed the Myval TAVR valve

Myval TAVR valve outperforms Sapien and Evolut in the late-breaking LANDMARK trial

The LANDMARK trial continues to show positive outcomes for the TAVR valve made in India.

A new alternative: Surgeons, cardiologists gather to learn about robotic aortic valve replacement

The WVU Heart and Vascular Institute is hosting a two-day symposium focused on exploring the benefits and long-term potential of robotic aortic valve replacement. Fans of the procedure say it represents a safe, effective alternative to TAVR and SAVR in patients with severe aortic stenosis.

Prosthesis-patient mismatch after TAVR may not negatively impact quality of life

Researchers warned that “aggressive procedural modifications” should not be necessary during TAVR to mitigate the risk of prosthesis-patient mismatch. This appears to be true for patients receiving both self-expanding and balloon-expandable TAVR valves.

TAVR

When heart patients can’t wait: Urgent TAVR with self-expanding vs. balloon-expandable valves

Cleveland Clinic launches partnership focused on AI-powered TAVR planning

Acute kidney injury after TAVR: Key risk factors every cardiologist should know

FDA approves JenaValve TAVR system for aortic regurgitation

Moderate valve oversizing during TAVR boosts survival—too much may be less beneficial